Omalizumab Products
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.513 alerts
Get alerted when Policy 5.01.513 changes without checking for updates manually.
Monitor payer policy activity
Medical and pharmacy benefit coverage and site-of-service medical necessity criteria for omalizumab products (Xolair and Omlyclo) for indications including moderate to severe persistent asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy; intended for providers and utilization review.
Updated initial authorization length for all reviews from 6 months to 12 months and removed reference to non-formulary exception reviews.
Added Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently with omalizumab for the treatment of asthma.
Updated chronic idiopathic urticaria dose limit to 600 mg every 2 weeks.
Updated asthma criteria to use maximum tolerated doses of inhaled corticosteroid rather than maximum doses and added FEV1/FVC < 0.80 as an option.
Updated CRSwNP criteria to require bilateral disease confirmed by exam, CT, or endoscopy and prior use of systemic corticosteroids in last 2 years or prior bilateral polyp surgery or contraindication to systemic steroids.
Clarified that medications listed are subject to the product's FDA dosage and administration prescribing information and that non-formulary exception authorizations may be approved up to 12 months.
Updated initial approval length for Xolair for chronic idiopathic urticaria to 6 months (historical change noted in 2023) then generalized initial authorization update to 12 months in 2026 update.
Initial authorization period for all reviews changed from 6 months to 12 months.
Added Exdensur (depemokimab-ulaa) to the list of medications that should not be used concurrently with omalizumab when treating asthma.
Chronic idiopathic urticaria dose limit updated to 600 mg every 2 weeks.
Policy title updated from "Xolair (omalizumab)" to "Omalizumab Products" and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.
Site of service medical necessity review can apply to injection drugs.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.